MEPE Antibody (F-7): sc-390828

MEPE Antibody (F-7) is a mouse monoclonal IgG2a antibody that detects MEPE (matrix extracellular phosphoglycoprotein) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). MEPE is a 525 amino acid extracellular matrix protein predominantly expressed in osteocytes and the brain, playing a crucial role in regulating bone metabolism by mediating mineralization and demineralization within the osteocyte microenvironment. MEPE features an RGD cell-attachment motif, which is essential for interaction with integrins, facilitating cell adhesion and signaling processes. This interaction is vital for maintaining bone integrity and promoting osteoblast and osteoclast activity, thereby influencing skeletal development and regeneration. MEPE′s involvement in these processes links MEPE to various developmental events, including skeletogenesis and odontogenesis, and MEPE secretion in hypophosphatemic osteomalacia tumors suggests a potential role in the pathophysiology of bone-related cancers. Furthermore, defects in the gene encoding MEPE have been associated with osteomalacia, a condition characterized by inadequate bone mineralization, highlighting MEPE′s importance in bone health and disease. Anti-MEPE antibody (F-7) serves as a valuable tool for researchers investigating the complex mechanisms of bone metabolism and related disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MEPE Antibody (F-7) References:

1. MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21.  |  MacDougall, M., et al. 2002. Connect Tissue Res. 43: 320-30. PMID: 12489176
2. Regulation of mRNA expression of matrix extracellular phosphoglycoprotein (MEPE)/ osteoblast/osteocyte factor 45 (OF45) by fibroblast growth factor 2 in cultures of rat bone marrow-derived osteoblastic cells.  |  Zhang, GX., et al. 2004. Endocrine. 24: 15-24. PMID: 15249699
3. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density.  |  Jain, A., et al. 2004. J Clin Endocrinol Metab. 89: 4158-61. PMID: 15292364
4. A fragment of the hypophosphatemic factor, MEPE, requires inducible cyclooxygenase-2 to exert potent anabolic effects on normal human marrow osteoblast precursors.  |  Nagel, DE., et al. 2004. J Cell Biochem. 93: 1107-14. PMID: 15449321
5. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM.  |  Addison, WN., et al. 2008. J Bone Miner Res. 23: 1638-49. PMID: 18597632
6. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator.  |  David, V., et al. 2009. Endocrinology. 150: 4012-23. PMID: 19520780
7. MEPE/OF45 as a new target for sensitizing human tumour cells to DNA damage inducers.  |  Zhang, P., et al. 2010. Br J Cancer. 102: 862-6. PMID: 20145617
8. A small peptide mimicking the key domain of MEPE/OF45 interacting with CHK1 protects human cells from radiation-induced killing.  |  Yu, X., et al. 2010. Cell Cycle. 9: 1981-5. PMID: 20436300
9. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.  |  Atkins, GJ., et al. 2011. J Bone Miner Res. 26: 1425-36. PMID: 21312267
10. Growth on Metallo-Supramolecular Coordination Polyelectrolyte (MEPE) Stimulates Osteogenic Differentiation of Human Osteosarcoma Cells (MG63) and Human Bone Marrow Derived Mesenchymal Stem Cells.  |  Belka, J., et al. 2019. Polymers (Basel). 11: PMID: 31252601

The preferred MEPE antibody is MEPE Antibody (LFMb-33): sc-73635.